Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.

Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, Fujino M, Yamakawa H, Nakatani Y, Tada Y, Shimada H, Tagawa M.

Am J Clin Pathol. 2013 Jan;139(1):39-46. doi: 10.1309/AJCPT94JVWIHBKRD.

PMID:
23270897
2.

Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.

Wu D, Hiroshima K, Yusa T, Ozaki D, Koh E, Sekine Y, Matsumoto S, Nabeshima K, Sato A, Tsujimura T, Yamakawa H, Tada Y, Shimada H, Tagawa M.

Ann Diagn Pathol. 2017 Feb;26:31-37. doi: 10.1016/j.anndiagpath.2016.10.010. Epub 2016 Oct 22.

PMID:
28038708
3.

BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.

Hwang HC, Pyott S, Rodriguez S, Cindric A, Carr A, Michelsen C, Thompson K, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2016 May;40(5):714-8. doi: 10.1097/PAS.0000000000000616.

PMID:
26900815
4.

FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.

Chung CT, Santos Gda C, Hwang DM, Ludkovski O, Pintilie M, Squire JA, Tsao MS.

J Clin Pathol. 2010 Jul;63(7):630-4. doi: 10.1136/jcp.2010.076794.

5.

p16 Deletion in sarcomatoid tumors of the lung and pleura.

Tochigi N, Attanoos R, Chirieac LR, Allen TC, Cagle PT, Dacic S.

Arch Pathol Lab Med. 2013 May;137(5):632-6. doi: 10.5858/arpa.2012-0108-OA.

PMID:
23627453
6.

Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.

Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, Murer B, Comin C, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle P, Popper H.

Virchows Arch. 2008 Dec;453(6):627-35. doi: 10.1007/s00428-008-0689-3. Epub 2008 Oct 29.

PMID:
18958493
7.

The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.

Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S.

Am J Clin Pathol. 2011 Apr;135(4):619-27. doi: 10.1309/AJCPP5R2ZJZKCLWN.

PMID:
21411785
8.

9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.

Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A.

Pathol Int. 2010 May;60(5):395-9. doi: 10.1111/j.1440-1827.2010.02534.x.

PMID:
20518890
9.

Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.

Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S.

Mod Pathol. 2008 Jun;21(6):742-7. doi: 10.1038/modpathol.2008.45. Epub 2008 Mar 7.

10.

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.

Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2016 Jan;40(1):120-6. doi: 10.1097/PAS.0000000000000529.

PMID:
26448191
11.

Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.

Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K.

Cancer Sci. 2015 Nov;106(11):1635-41. doi: 10.1111/cas.12769. Epub 2015 Oct 15.

12.

Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.

Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, Katayama H, Takigawa N, Kiura K, Tanimoto M, Kishimoto T.

Cancer Sci. 2012 Mar;103(3):510-4. doi: 10.1111/j.1349-7006.2011.02180.x. Epub 2012 Jan 13.

13.

Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.

Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, Marukawa K, Matsuno Y, Taguchi K, Tsujimura T.

Cancer Cytopathol. 2013 Aug;121(8):415-22. doi: 10.1002/cncy.21269. Epub 2013 Feb 28.

14.

[Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].

Liu Y, Chen X, Ding N, Xu W, Yang H, Chen X.

Zhonghua Bing Li Xue Za Zhi. 2015 Apr;44(4):262-5. Chinese.

PMID:
25975910
15.

BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.

M McGregor S, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T.

Hum Pathol. 2017 Feb;60:86-94. doi: 10.1016/j.humpath.2016.09.026. Epub 2016 Oct 19.

PMID:
27771374
16.

D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.

Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H.

Mod Pathol. 2007 Feb;20(2):248-55.

17.

p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.

Hwang H, Tse C, Rodriguez S, Gown A, Churg A.

Am J Surg Pathol. 2014 May;38(5):681-8. doi: 10.1097/PAS.0000000000000176.

PMID:
24503757
18.

The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.

Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, Yamamoto H, Asano H, Tsukuda K, Kishimoto T, Otsuki T, Miyoshi S.

Lung Cancer. 2013 Dec;82(3):485-90. doi: 10.1016/j.lungcan.2013.09.017. Epub 2013 Oct 10.

19.

c-Met expression and MET amplification in malignant pleural mesothelioma.

Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC.

Ann Diagn Pathol. 2016 Aug;23:1-7. doi: 10.1016/j.anndiagpath.2016.04.007. Epub 2016 Apr 30.

PMID:
27402216
20.

p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.

Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, Shimao Y, Marutsuka K, Moriguchi S, Maruyama R, Miyamoto S, Nabeshima K.

Am J Clin Pathol. 2015 Jun;143(6):830-8. doi: 10.1309/AJCPOATJ9L4GCGDA.

PMID:
25972325

Supplemental Content

Support Center